Paul Frith

Paul Frith is Co-Founder and Director of Performance Measurement & Analytics at Rubica.

Latest articles

Phase III trial results of PT010 combination therapy in COPD

AstraZeneca has announced publication of results from the KRONOS Phase III trial which evaluated the efficacy and safety of triple combination therapy PT010 (budesonide/...

Brands by numbers: Launch excellence in an increasingly specialised world

As the focus turns to specialist therapy areas and competition increases, achieving a successful launch is becoming even more challenging.

Pharmaceutical job opportunities: Star recruits for ground-breaking product launch

Star, the UK's first choice outsourcing and resourcing provider to the pharmaceutical, medical device and healthcare industries is delighted to announce a new partnership. Through...